ARS PHARMACEUTICALS INC (SPRY) Forecast, Price Target & Analyst Ratings

NASDAQ:SPRY • US82835W1080

Current stock price

8.3 USD
+0.19 (+2.34%)
At close:
8.14 USD
-0.16 (-1.93%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARS PHARMACEUTICALS INC (SPRY).

Forecast Snapshot

Consensus Price Target

Price Target
$27.20
+ 227.71% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 12, 2026
Period
Q1 / 2026
EPS Estimate
-$0.51
Revenue Estimate
23.572M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
88.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$27.20
Upside
+ 227.71%
From current price of $8.30 to mean target of $27.20, Based on 12 analyst forecasts
Low
$12.12
Median
$28.56
High
$35.70

Price Target Revisions

1 Month
-5.33%
3 Months
-4.19%

Price Target Summary

12 Wall Street analysts provided a forecast for the next 12 months for SPRY. The average price target is 27.2 USD. This implies a price increase of 227.71% is expected in the next year compared to the current price of 8.3.
The average price target has been revised downward by 4.19% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

SPRY Current Analyst RatingSPRY Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

SPRY Historical Analyst RatingsSPRY Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
88.33%
SPRY was analyzed by 12 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about SPRY.
In the previous month the buy percentage consensus was at a similar level.
SPRY was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-09-04Roth CapitalInitiate Buy
2025-03-07ScotiaBankInitiate Sector Outperform
2025-01-14Raymond JamesMaintains Strong Buy -> Strong Buy
2025-01-13Leerink PartnersMaintains Outperform -> Outperform
2024-10-08Cantor FitzgeraldReiterate Overweight -> Overweight
2024-09-20Leerink PartnersMaintains Outperform -> Outperform
2024-09-16Cantor FitzgeraldReiterate Overweight -> Overweight
2024-09-09Cantor FitzgeraldReiterate Overweight -> Overweight
2024-08-20Cantor FitzgeraldInitiate Overweight
2024-08-13Raymond JamesUpgrade Outperform -> Strong Buy
2024-07-25Raymond JamesInitiate Outperform
2024-03-11WedbushReiterate Outperform -> Outperform
2024-03-05Leerink PartnersUpgrade Market Perform -> Outperform
2023-11-13WedbushMaintains Outperform -> Outperform
2023-09-21WedbushMaintains Outperform -> Outperform
2023-09-20William BlairDowngrade Outperform -> Market Perform
2023-08-14WedbushReiterate Outperform -> Outperform
2023-06-21WedbushMaintains Outperform -> Outperform
2023-05-18WedbushReiterate Outperform -> Outperform
2023-05-12WedbushReiterate Outperform -> Outperform
2023-05-10WedbushReiterate Outperform
2023-01-31WedbushInitiate Outperform
2023-01-04William BlairInitiate Outperform
2022-12-13SVB LeerinkInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 12, 2026
Period
Q1 / 2026
EPS Estimate
-$0.51
Revenue Estimate
23.572M
Revenue Q2Q
195.65%
EPS Q2Q
-46.59%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
-9.09%
Revenue (3 Months)
-8.78%
EPS (1 Month)
-4.25%
EPS (3 Months)
-6.46%

Next Earnings Summary

SPRY is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.51 USD and the consensus revenue estimate is 23.57M USD.
The next earnings revenue estimate has been revised downward by 8.78% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
SPRY revenue by date.SPRY revenue by date.
30K
-97.73%		89.149M
297,063.33%		84.278M
-5.46%		160.77M
90.76%		292.12M
81.70%		412.09M
41.07%		620.33M
50.53%		781.98M
26.06%		764.77M
-2.20%		881.94M
15.32%		1.059B
20.08%
EBITDA
YoY % growth
SPRY ebitda by date.SPRY ebitda by date.
-67.447M
-91.61%		-3.004M
95.55%		-178.081M
-5,828.13%		-14.637M
91.78%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
SPRY ebit by date.SPRY ebit by date.
-67.52M
-90.09%		-3.083M
95.43%		-179.448M
-5,720.56%		-158.132M
11.88%		-68.553M
56.65%		8.539M
112.46%		182M
2,031.40%		308.26M
69.37%		254.4M
-17.47%		345.55M
35.83%		481.46M
39.33%
Operating Margin
SPRY operating margin by date.SPRY operating margin by date.
-225,066.67%-3.46%-212.92%-98.36%-23.47%2.07%29.34%39.42%33.26%39.18%45.46%
EPS
YoY % growth
SPRY eps by date.SPRY eps by date.
-0.57
41.84%		0.05
108.77%		-1.75
-3,600.00%		-1.43
18.01%		-0.23
83.65%		0.40
269.57%		0.03
-92.31%		0.45
1,366.67%		0.88
95.45%		1.45
65.12%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.51
-46.59%		-0.40
13.30%		-0.26
49.24%		-0.41
1.64%		-0.42
18.49%		-0.17
56.52%		0.23
188.87%		-0.06
85.19%
Revenue
Q2Q % growth		23.572M
195.65%		39.432M
150.89%		58.164M
78.96%		39.74M
41.49%		50.23M
113.09%		80.565M
104.31%		125.41M
115.61%		87.317M
119.72%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-51.527M
-38.60%		-39.924M
16.15%		-25.905M
51.30%		-40.776M
1.66%		-32.028M
37.84%		-8.874M
77.77%		30.702M
218.52%		-4.59M
88.74%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
30.60%
EPS Next 5 Year
17.68%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
70.36%
Revenue Next 5 Year
56.48%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ARS PHARMACEUTICALS INC / SPRY Forecast FAQ

What do analysts expect the price target to be for ARS PHARMACEUTICALS INC (SPRY)?

12 analysts have analysed SPRY and the average price target is 27.2 USD. This implies a price increase of 227.71% is expected in the next year compared to the current price of 8.3.

Can you provide the upcoming earnings date for ARS PHARMACEUTICALS INC?

ARS PHARMACEUTICALS INC (SPRY) will report earnings on 2026-05-12, after the market close.

What are the consensus estimates for ARS PHARMACEUTICALS INC (SPRY) next earnings?

The consensus EPS estimate for the next earnings of ARS PHARMACEUTICALS INC (SPRY) is -0.51 USD and the consensus revenue estimate is 23.57M USD.

How do analysts rate ARS PHARMACEUTICALS INC (SPRY)?

The consensus rating for ARS PHARMACEUTICALS INC (SPRY) is 88.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.